Completing data — refresh the page later to see the latest
80863-62-3C[C@@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)NC1C(C)(C)SC1(C)CIVBOUFAWPCPFTQ-SFYZADRCSA-NAlitame is a dipeptide.
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
HistoryAlitame, L-α-aspartyl-D-alanine N-(2,2,4,4-tetra methylthietan-3-yl)amide (5), was developed by Pfizer, but is owned by Danisco now. In 1986, Pfizer filed a food additive petition with the FDA. As of 2006, it was still pending. Alitame was approved for use as a sweetener by Australia in 1993, by China, Mexico, and New Zealand in 1994, by Indonesia in 1995, and by Colombia in 1996.
UsesNon-nutritive sweetener.
UsesAlitame [L-a-aspartyl-N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alaninamide] is a sweetener based on an amino acid. It is a very intense sweetener, possessing a sweetening power of about 2000 times that of sucrose. It also exhibits a clean sweet taste similar to sucrose. Although it is metabolized, so little is needed that its caloric contribution is insignificant. Alitame is prepared from the amino acids, L-aspartic acid, D-alamine, and a novel amine.
UsesAlitame is a dipeptide amide derivative of aspartic acid used as an artificial sweetener. Alitame is about ten times sweeter than Aspartame (A790015) with a half life about twice as long.
DefinitionChEBI: Alitame is a dipeptide.
80863-62-3DTXSID3043780CHEMBL2104004CHEBI:184021